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Abstract
Background: The local anesthetic lidocaine can affect intra- and extra-cellular signaling pathways in both neuronal
and non-neuronal cells, resulting in long-term modulation of biological functions, including cell growth and death.
Indeed, lidocaine was shown to induce necrosis and apoptosis in vitro. While several studies have suggested that
lidocaine-induced apoptosis is mitochondrial pathway-dependent, it remains unclear whether reactive oxygen
species (ROS) are involved in this process and whether the observed cell death can be prevented by antioxidant
treatment.
Methods: The effects of lidocaine and antioxidants on cell viability and death were evaluated using SH-SY5Y
cells, HeLa cells, and HeLa cell derivatives. Cell viability was examined via MTS/PES ([3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]/phenazine ethosulfate) assay. Meanwhile, cell
apoptosis and necrosis were evaluated using a cell death detection assay with Annexin V-FITC and PI staining, as
well as by assaying for caspase-3/7 and caspase-9 activity, and by measuring the release of lactate dehydrogenase,
respectively. Mitochondrial transmembrane potential (ΔΨm) was assessed using the fluorescent probe
tetramethylrhodamine ethyl ester.
Results: Lidocaine treatment resulted in suppression of the mitochondrial electron transport chain and subsequent
attenuation of mitochondrial membrane potential, as well as enhanced ROS production, activation of caspase-3/7
and caspase-9, and induction of apoptosis and necrosis in SH-SY5Y cells in a dose- and time-dependent manner.
Likewise, the anesthetics mepivacaine and bupivacaine also induced apoptosis in SH-SY5Y cells. Notably, the
antioxidants N-acetyl cysteine (NAC) and Trolox successfully scavenged the mitochondria-derived ROS and
suppressed local lidocaine-induced cell death.
Conclusions: Our findings demonstrate that the local anesthetics lidocaine, mepivacaine, and bupivacaine inhibited
the activity of mitochondria and induced apoptosis and necrosis in a dose-dependent manner. Furthermore, they
demonstrate that treatment with the antioxidants NAC, Trolox, and GGA resulted in preservation of mitochondrial
voltage and inhibition of apoptosis via suppression of caspase activation.
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Background
There is an established consensus that local anesthetics
exert nerve-blocking activity, primarily through the inhib-
ition of voltage-gated sodium channels [1]. However, these
compounds can also affect the intra- and extra-cellular
signaling pathways of both neuronal and non-neuronal
cells, resulting in long-term modulation of biological func-
tions, including cell growth and death [2]. Lidocaine is a
widely used local anesthetic and anti-arrhythmic agent.
Notably, lidocaine was also shown to induce apoptosis
and necrosis both in vitro [3–5] and in vivo [6], and to
cause transient or permanent nerve injury, such as cauda
equina syndrome, after spinal anesthesia in clinical set-
tings [7, 8]. In addition, it was reported that lidocaine in-
hibits the invasive ability of cancer cells at concentrations
used for surgical operations (5–20 mM).
Apoptosis is a form of programmed cell death that is
characterized by a series of distinct morphological and
biochemical changes, and is an important process in a
wide variety of biological systems. There are two major
signaling pathways by which apoptosis is induced: the
intrinsic and extrinsic pathway. While the extrinsic path-
way is dependent on cell-surface death receptors such as
Fas (First apoptosis signal), the intrinsic pathway is initiated
within mitochondria [9]. Specifically, in the intrinsic path-
way, the formation of a multimeric Apaf-1/cytochrome c
complex results in activation of caspase-9, which in
turn cleaves and activates the downstream caspases
caspase-3, −6, and −7 [1, 10]. Notably, reactive oxy-
gen species (ROS) are widely believed to play an es-
sential role in apoptosis. Indeed, several studies
indicate that ROS scavengers, including the synthetic
compound N-acetyl cysteine (NAC) and the endogen-
ous redox-active molecule thioredoxin (TRX), can be
used to alleviate intracellular ROS and thereby pre-
vent apoptosis and necrosis.
Previous studies demonstrated that lidocaine-induced
cell death is dependent on the mitochondrial pathway;
however, it is still largely unclear whether ROS are in-
volved in this process. In this study, we demonstrate that
in vitro lidocaine treatment resulted in attenuation of
mitochondrial membrane potential and promoted
caspase-dependent apoptosis in neuronal SH-SY5Y
cells. Moreover, we show that the observed increases in
cell death were mitochondria-derived ROS-dependent and




Lidocaine, mepivacaine, bupivacaine, NAC, and (±)-6-
Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid
(Trolox) were obtained from Sigma-Aldrich (St. Louis,
MO, USA), teprenone (geranylgeranylacetone, GGA) was
obtained from Wako Pure Chemical Industries (Osaka,
Japan), and recombinant human TRX (rhTRX) was ob-
tained from Oriental Yeast Co., Ltd. (Tokyo, Japan). GGA
and Trolox were dissolved in absolute ethanol, while
bupivacaine and NAC were dissolved in H2O, and
rhTRX was dissolved in citric acid. Rotenone, oligo-
mycin and antimycin A were obtained from Abcam, Inc.
(Cambridge, MA, USA).
Cell culture
All cell lines were obtained from American Type Culture
Collection (ATCC; Manassas, VA, USA). The established
cell lines derived from human neuroblastoma SH-SY5Y
cells and cervical carcinoma HeLa cells were maintained
in Roswell Park Memorial Institute (RPMI) 1640 medium
supplemented with 10 % fetal bovine serum, 100 units/ml
penicillin, and 0.1 mg/ml streptomycin. The characteris-
tics of EB8 cells (HeLa cells lacking mtDNA) and HeEB1
cells (a hybrid clone of EB8 cells containing mtDNA from
wild-type HeLa cells) have been described elsewhere
[11, 12]. All cells were maintained at 37 °C in a hu-
midified atmosphere containing 5 % CO2. Cells were
grown in 100 mm dishes and were subcultured for
experiments when they reached 85 % confluence.
Cell viability assay (MTS assay)
Cell viability was assessed using a CellTiter 96™ AQue-
ous One Solution Cell Proliferation Assay (Promega,
Madison, WI, USA). Briefly, SH-SY5Y cells were seeded
into 96-well plates (2 × 104 cells/well) and cultivated
overnight. The following day, cells were treated with the
indicated concentrations of the appropriate drug(s) for
varying lengths of time. After treatment, 20 μl of CellTi-
ter 96 AQueous One Solution™ Reagent was added to
each well, the plates were incubated at 37 °C for 1 h,
and the absorbance of each sample was measured using
an iMark™ Micropate Reader (BIO-RAD, Hercules, CA,
USA) at a wavelength of 490 nm. Cell viability was then
calculated by comparing the absorbance of treated cells
with that of the control cells (incubated without drugs),
which was defined as 100 % [13, 14]. All samples were
tested in triplicate for each experiment.
Caspase-3/7 and caspase-9 activity assays
The levels of caspase-3/7 and caspase-9 activity were
assessed using an Apo-ONE™ Homogeneous Caspase-3/7
Assay Kit (Promega) and a Caspase-Glo™ 9 Assays Kit
(Promega), respectively, according to the manufacturer’s
protocols. Briefly, SH-SY5Y cells were seeded into 96-well
plates (2 × 104 cells/well) and incubated overnight. The fol-
lowing day, cells were treated with the indicated concen-
trations of the appropriate drug(s) for varying lengths of
time. After treatment, 100 μl of Apo-ONE Caspase-3/7 Re-
agent™ or Caspase-Glo 9 reagent™ was added to each well,
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respectively. Cells were incubated at room temperature for
1 h and the luminescence of each well was measured using
an EnSpire™ Multimode Plate Reader (PerkinElmer,
Waltham, MA, USA). Caspase activity was then calculated
by comparing the levels of luminescence of the treated
cells with that of the control cell population (incubated
without drugs), which was defined as 100 %. Assays were
performed in triplicate at least twice. Data were expressed
as means ± standard deviations (SD).
Immunoblot assays
Whole cell lysates were prepared as described previously
[15, 16]. Briefly, cells were lysed by suspension in ice-cold
lysis buffer [0.1 % sodium dodecyl sulfate (SDS), 1 %
NP40, 5 mM ethylene diamine tetraacetic acid (EDTA),
150 mM NaCl, 50 mM Tris-Cl (pH 8.0), 1 mM sodium
orthovanadate, and Complete Protease Inhibitor™ (Roche
Applied Science)] and centrifuged at 10,000 × g to pellet
cell debris. Approximately 25 μg of each protein sample
was then separated by SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) and subjected to immunoblot
analysis using rabbit polyclonal antibodies specific to
PARP [poly (ADP-ribose) polymerase; 1:1,000] or cleaved
caspase-9 (Asp315; 1:1,000) (Cell Signaling Technology,
Danvers, MA, USA) [17], β-actin (Sigma-Aldrich), and
anti-rabbit IgG horseradish peroxidase-linked secondary
antibodies (1:2000 dilution; Cell Signaling Technology).
Immunolabeled proteins were then visualized using en-
hanced chemiluminescence (ECL™) reagents (Amersham
Biosciences, Little Chalfont, UK).
Analysis of cell apoptosis
Levels of cell apoptosis were measured using an Annexin
V-FITC Apoptosis Detection Kit™ (BioVision, Milpitas,
CA, USA), according to the manufacturer’s instructions.
For these analyses, SH-SY5Y cells were seeded into 6-well
plates (3 × 105 cells/well) and incubated overnight. The fol-
lowing day, cells were treated with the indicated concentra-
tions of the appropriate drug(s) for varying lengths of time
and harvested by centrifugation at 1200 rpm for 3 min.
The culture supernatants were discharged, and the result-
ing pellets were suspended in a mixture comprised of
500 μl binding buffer, 5 μl Annexing V-FITC, and 5 μl pro-
pidium iodide (PI; 50 μg/ml) for 5 min at room
temperature in the dark and analyzed using a FACSCalibur
flow cytometer (BD Biosciences, San Jose, CA, USA)
equipped with CellQuest Pro™ software [4, 13]. Data were
evaluated using FlowJo™ version 7.6.3 software (TreeStar,
Ashland, OR, USA), exported to Excel spreadsheets, and
subsequently analyzed using the statistical application R.
Lactate dehydrogenase (LDH)-based cytotoxic assay
Levels of cell cytotoxicity were evaluated using a
CytoTox-ONE™ Kit (Promega). Briefly, SH-SY5Y cells
were seeded into 96-well plates (2 × 104 cells/well) and
incubated overnight. The following day, cells were
treated with the indicated concentrations of the appro-
priate drug(s) for varying lengths of time. Twenty micro-
liters of CytoTox-ONE™ reagent was added to each well,
plates were incubated at 22 °C for 10 min, and then
50 μl of Stop Solution was added to each well. The
resulting fluorescence was measured using an EnSpire™
Multimode Plate Reader (PerkinElmer) at an excitation
wavelength of 560 nm and an emission wavelength of
590 nm. Percentages of cell death were calculated by
comparing the level of LDH released (fluorescence
value) from each treatment group with that of the posi-
tive control population (cells treated with Lysis solution),
which was defined as 100 %. Meanwhile, the level of
LDH released from the negative control population
(untreated cells) was defined as 0 %. All samples were
evaluated in triplicate for each experiment.
Determination of mitochondrial membrane potential
(ΔΨm)
Mitochondrial membrane potential was determined
by flow cytometry using a MitoPT™ JC-1 Assay Kit
(ImmunoChemistry Technologies, Bloomington, MN,
USA), according to the manufacturer’s instructions. For
these analyses, SH-SY5Y cells were seeded into 6-well
plates (3 × 105 cells/well) and cultivated overnight. The
following day, cells were treated with the indicated con-
centrations of the appropriate drug(s) for varying lengths
of time and then pelleted by centrifugation at 1200 rpm
for 3 min. Supernatants were discharged, and cells were
resuspended in JC-1, incubated at 37 °C for 15 min in the
dark, and collected by centrifugation at 1200 rpm for
3 min. Supernatants were again discharged and the
remaining cell residues were suspended in 500 μl assay
buffer. Samples were subsequently analyzed using a
FACSCalibur flow cytometer (BD Biosciences, San Jose,
CA, USA) equipped with CellQuest Pro™ software [4, 13]
for the detection of red JC-1 aggregates (590 nm emission)
or green JC-1 monomers (527 nm emission). The result-
ing data were evaluated using FlowJo version 7.6.3 soft-
ware (TreeStar, San Carlos, CA), exported to Excel
spreadsheets, and subsequently analyzed using the statis-
tical application R.
Measurement of total cellular O2 consumption rate (OCR)
Total OCR was measured as described previously [12, 16].
Briefly, SH-SY5Y cells were trypsinized and suspended at a
concentration of 1 × 107 cells/ml in RPMI containing 10 %
FBS and 25 mM HEPES buffer. For each experiment,
equal numbers of cells (suspended in 1 ml) were pi-
petted into the chamber of an Oxytherm electrode
unit (Hansatech Instruments, Norfolk, UK), which uses a
Clark-type electrode to monitor the concentration of
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dissolved O2 in the sealed chamber over time. The test re-
agents including lidocaine, rotenone and FCCP were
added into the chambers immediately before each meas-
urement. The resulting data were exported to a computer-
ized chart recorder (Oxygraph; Hansatech Instruments),
which calculated the OCR values. The temperature was
maintained at 25 °C during measurement. The concentra-
tions of O2 in 1 ml of DMEM medium lacking cells was
also measured over time and utilized as the background.
O2 consumption experiments were repeated at least three
times, and data were expressed as means ± SD [12].
Live cell ROS imaging
For evaluation of intracellular ROS generation, control
and lidocaine-treated SH-SY5Y cells were treated with the
ROS-sensitive dye 2', 7'-dichlorodihydrofluorescin diace-
tate (DCFH-DA) and analyzed using a BioStation IM live
cell time-lapse imaging system (Nikon, Tokyo, Japan) at
37 °C and 5 % CO2; phase-contrast and fluorescence im-
ages were acquired at 15 min intervals [18, 19].
Statistical analysis
All experiments were repeated at least twice and each
sample was evaluated in triplicate. Representative data,
expressed as means ± SD, are shown. Differences
between results were evaluated by one-way analysis of
variance (ANOVA) or two-way ANOVA, followed by
Dunnett’s test for multiple comparisons. All statistical
analyses were performed using EZR (Saitama Medical
Center, Jichi Medical University), which is a graphical
user interface for R (The R Foundation for Statistical
Computing, version 3.1.3) [20]. More precisely, it is a
modified version of R commander software (version
1.6–3) and includes statistical functions that are fre-
quently used in biostatistics. P-values < 0.05 were consid-
ered statistically significant. All graphs were generated
by the application Prism 6 for Mac OS X (GraphPad
Software Inc., La Jolla, CA USA).
Results




phenazine ethosulfate) assays were utilized to investigate
the effects of lidocaine on neuronal cell proliferation or via-
bility. In this assay, the NADPH and NADH produced by
dehydrogenase enzymes of metabolically active cells biore-
duce the MTS tetrazolium compound (Owen’s reagent)
into a colored formazan product that is soluble in tissue
culture medium. Treatment with 1 mM, 4 mM, and
10 mM lidocaine significantly suppressed SH-SY5Y cell via-
bility at 12 h, 24 h, and 48 h after administration in both a
dose- and time-dependent manner (Fig. 1a). In contrast,
100 μM lidocaine had no effect on cell viability (Fig. 1a). To
elucidate the mechanism by which lidocaine suppresses cell
viability, we evaluated the effect of this compound on the
levels of apoptosis in SH-SY5Y cells. Notably, treatment
with 4 mM or 10 mM lidocaine resulted in significant in-
creases in caspase-3/7 activation after 12 h, 24 h, and 48 h
(Fig. 1b), while treatment with 4 mM and10 mM lidocaine
yielded statistically significant activation of caspase-9
(Fig. 1c), as well as increased levels of cleaved PARP and
caspase-9 (Fig. 1d), after 24 h.
To confirm these findings, SH-SY5Y cells were stained
with PI and FITC-conjugated annexin V and evaluated
by flow cytometry. Cells treated with 4 mM or 10 mM
lidocaine exhibited significantly increased numbers of
PI-positive or annexin V-positive cells after 12 h and
24 h of treatment (Fig. 1e and Additional file 1: Figure
S1A–S1E). Additionally, treatment with 4 mM or
10 mM lidocaine resulted in significant reductions in
mitochondrial voltage (Fig. 1f and Additional file 2:
Figure S2A–S2D), while treatment with 10 mM lido-
caine resulted in significant increases in SH-SY5Y cell
death after 12 h, as indicated by the levels of LDH
release (Fig. 1g).
Critical involvement of mitochondria in lidocaine-induced
cell death
We next examined the effects of lidocaine treatment on
HeLa cervical carcinoma cells, as well as the HeLa-derived
cell lines EB8, which lack mitochondrial DNA (ρ0 cells),
and HeEB1, a hybrid clone of EB8 cells containing mtDNA
from wild-type HeLa cells. Compared to HeLa cells and
HeEB1, EB8 cells exhibited lower levels of O2 consumption
(Additional file 3: Figure S3A). Meanwhile, treatment with
4 mM and 10 mM lidocaine resulted in significant increases
in caspase-3/7 activation and cell death in both HeLa cells
(Fig. 2a) and HeEB1 cells after 24 h, compared to the con-
trol population (Additional file 3: Figure S3B and S3C).
Conversely, only 10 mM lidocaine treatment induced
caspase-3/7 activation in the EB8 ρ0 cell line (Fig. 2a).
Notably, however, treatment with 10 mM lidocaine resulted
in significantly higher levels of caspase-3/7 activity in HeLa
cells than in EB8 cells. Moreover, flow cytometry analysis
detected no significant difference in the levels of cell death
between the untreated EB8 ρ0 control population and the
population subjected to 4 mM-lidocaine treatment, indicat-
ing that, in contrast to the parental HeLa cell line, EB-8
cells are resistant to low levels of lidocaine (Fig. 2b). These
results prompted us to examine the involvement of mito-
chondria in lidocaine-induced cell death. First, we investi-
gated the effect of lidocaine on oxygen consumption in SH-
SY5Y cells; compared with the untreated control popula-
tion, SH-SY5Y cells treated with 4 mM and 10 mM lido-
caine exhibited reduced OCRs (Fig. 2c). We next evaluated
the effects of mitochondrial ETC. inhibitors, including
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100 nM rotenone, 2.5 μg/ml oligomycin, and 4 μM antimy-
cin A, on SH-SY5Y cells. As expected, each of these three
reagents significantly suppressed MTS conversion (Fig. 2d).
Treatment with 1 mM lidocaine or each ETC. inhibitors
did not elicit caspase 3/7 activation or ROS generation in
SH-SY5Y cells (Fig. 2e and f). Notably co-treatment with
1 mM lidocaine and rotenone effectively induced the
caspase activation. (Fig. 2e and f). In this study, we used
three types of ETC inhibitors. Although all the ETC
inhibitors increased caspase 3/7 activity and ROS
generation, only rotenone exerted statistically signifi-
cant effect. Rotenone is a Complex I inhibitor. Oligo-
mycin is an ATP synthase inhibitor. Antimycin A is a








Fig. 1 Lidocaine induces SH-SY5Y cell death in a dose- and time-dependent manner. Neuronal SH-SY5Y cells were exposed to the indicated
concentrations (0.1, 1, 4, or 10 mM) of lidocaine for varying lengths of time (0, 12, 24, and 48 h). a Graphic depiction of the levels of cell viability
of treated and untreated cells at each time point, as evaluated by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium] assay analysis (n = 4). b and c Graphic depictions of caspase-3/7 (n = 3) and caspase-9 (n = 5) activity in each treatment group at
different time points, as determined using an Apo-ONE™ Homogeneous Caspase-3/7 Assay Kit and a Caspase-Glo™ 9 Assays Kit, respectively. d
Immunoblot analysis of the levels of poly (ADP-ribose) polymerase (PARP), cleaved caspase-9 and β-actin in the lysates of treated and untreated
cells after 24 h. The blots are derived from two independent experiments. e Treated and untreated cells were harvested, and the levels of cell
death were analyzed by flow cytometry. The ratio of propidium iodide (PI)-positive and/or annexin V-positive cells [(Q1 + Q2 + Q4)/(Q1 + Q2 + Q3 +
Q4)] was used to calculate the percentage of dead cells (Additional file 1: Figure S1) (n = 3). f Graphic depiction of the average mitochondrial
membrane potential (ΔΨm) of treated and untreated cells (n = 3) at each time point, as measured using a MitoPT™ JC-1 Assay Kit. Values indicate the
ratio [Q2/(Q2 + Q4)] of green JC-1 monomers (527 nm emission) to red aggregates (590 nm emission). g Graphic depiction of the levels of cell death
among treated and untreated cell populations. Cell death was evaluated by measuring the levels of lactate dehydrogenase (LDH) within culture
supernatants (n = 4). Control was treated by the lysis buffer. Data presented in a–c and e–g are expressed as means ± standard deviations (SD). Differences
between results were evaluated by two-way ANOVA (a, b, e and f), followed by Dunnett’s test for multiple comparisons in each group and one-way
ANOVA (c and g) followed by Dunnett’s test for multiple comparisons. *p < 0.05 compared with the control cell population at incubation time 0 h
(no treatment). #p < 0.05 compared with the control cell population at the same time period (group)
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investigation to clearly elucidate the target(s) of lido-
caine and the mechanism of the synergistic effect of
lidocaine and ETC inhibitors.
These findings are therefore consistent with those ob-
tained by flow cytometry and indicate that lidocaine pro-




Fig. 2 Critical involvement of mitochondria in lidocaine-induced cell death. HeLa cells and EB8 cells (HeLa cells lacking mitochondrial DNA) were
exposed to the indicated concentrations of lidocaine (0, 0.1, 1, 4, or 10 mM) for 24 h. a Graphic depiction of the levels of caspase-3/7 activity in
each treatment group, as determined using an Apo-ONE Homogeneous Caspase-3/7 Assay Kit™ (n = 4). b Treated and untreated cells were
harvested, and the levels of cell death were analyzed by flow cytometry (n = 4). The ratio with propidium iodide (PI)- or annexin V-positive
cells [(Q1 + Q2 + Q4)/(Q1 + Q2 + Q3 + Q4)] were indicated as dead cells (Additional file 1: Figure S1). c Graphic depiction of the oxygen
consumption rate (OCR) in untreated SH-SY5Y cells and cells treated with lidocaine (0.1, 1, 4, or 10 mM), rotenone (100 nM), or carbonyl
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (50 nM). Values are presented as ratios of OCR compared to that in the control (without
lidocaine treatment) group (n = 4). d and e Graphic depiction of the levels of cell viability among SH-SY5Y cells treated with mitochondrial ETC
inhibitors. Cells were treated with 1 mM lidocaine and either 100 nM rotenone, 2.5 μg/ml oligomycin, or 4 μM antimycin A, and subjected to (d) MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay (n = 3) or (e) caspase-3/7 activity assay (n = 3) analysis.
f Graphic depiction of reactive oxygen species (ROS) production in SH-SY5Y cells exposed to 1 mM lidocaine in the presence or absence of 100 nM
rotenone, 2.5 μg/ml oligomycin and 4 μM antimycin A for 6 h (n = 3). Data depict the ratio of ROS production in treated cells compared to that in the
untreated control group. All data were expressed as means ± standard deviations (SD). Differences between results were evaluated by two-way analysis
of variance (ANOVA) (a, b, e and f) followed by Dunnett’s test for multiple comparisons in each group or one-way ANOVA (c and d),
followed by Dunnett’s test for multiple comparisons. #p < 0.05 compared with the control treatment population in the same group
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Effect of synthetic antioxidants on lidocaine-induced cell
death
Several reports have indicated that ROS play a critical
role in mitochondria-dependent cell death. As demon-
strated in Fig. 3a, 4 mM and 10 mM lidocaine treatment
induced ROS accumulation in SH-SY5Y cells within 6 h.
Notably, however, these increases in ROS were blocked
upon treatment with the antioxidant NAC (Fig. 3a). We
therefore further examined the effects of the antioxidant
NAC on SH-SY5Y cells. Treatment with 10 mM NAC
blocked the suppression of SH-SY5Y viability observed




Fig. 3 Effect of synthetic antioxidants on lidocaine-induced cell death. a Graphic depiction of reactive oxygen species (ROS) production in
SH-SY5Y cells exposed to the indicated concentrations of lidocaine (0, 0.1, 4, or 10 mM) for 6 h (n = 3) in the presence or absence of 10 mM
N-acetyl cysteine (NAC). Data depict the ratio of ROS production in treated cells compared to that in the untreated control group. b–e SH-SY5Y
cells were exposed to the indicated concentrations of lidocaine (0, 4, or 10 mM) for 24 h in the presence or absence of NAC (4 or 10 mM). b
Cell viability and (c) caspase-3/7 activity were evaluated by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] assay (n = 3) and Apo-ONE™ Homogeneous Caspase-3/7 Assay (n = 3) analysis, respectively. d Cells were harvested and lysates
were subjected to immunoblot assay analysis using antibodies specific to poly (ADP-ribose) polymerase (PARP) and cleaved caspase-9. e Graphic
depiction of the levels of cell death among treated and untreated cell populations, as evaluated by flow cytometry (n = 4). The ratio with PI or
annexin V positive cells [(Q1 + Q2 + Q4)/(Q1 + Q2 + Q3 + Q4)] were indicated as dead cells (Additional file 1: Figure S1). f SH-SY5Y cells were
exposed to the indicated concentrations of lidocaine (0.1, 1, 4, or 10 mM) in the presence or absence of 250 μM Trolox for 24 h, and subjected to
caspase-3/7 activity assay analysis (n = 4) (left panel). Graphic depiction of the levels of cell death among treated and untreated cell populations,
as evaluated by flow cytometry (n = 3) (right panel). The ratio with PI or annexin V positive cells [(Q1 + Q2 + Q4)/(Q1 + Q2 + Q3 + Q4)] were
indicated as dead cells. Differences between results were evaluated by one-way analysis of variance (ANOVA) (a) followed by Dunnett’s test for
multiple comparisons or two-way ANOVA (b, c, e and f) followed by Dunnett’s test for multiple comparisons in each group. *p < 0.05 compared
with the control cell population at 0 h (no treatment). #p < 0.05 compared with the control treatment population in the same group
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NAC inhibited the 4 mM lidocaine-induced increase in
caspase-3/7 activity (Fig. 3c) in a dose-dependent manner.
While neither 4 mM nor 10 mM NAC treatment had any
significant effect on the suppression of cell viability medi-
ated by 10 mM lidocaine treatment (Fig. 3b), the levels of
caspase-3/7 activation induced by 10 mM lidocaine were
partially suppressed by exposure to 4 mM and 10 mM
NAC (Fig. 3c). Similar effects were observed in SH-SY5Y
cells treated with another antioxidant, Trolox (250 μM;
Fig. 3f). 250 μM Trolox suppressed ROS generation elicited
by 4 mM lidocaine (Additional file 3: Figure S3E). 250 μM
Trolox treatment significantly suppressed 4 mM-lidocaine
induced cell death but not 10 mM-lidocaine induced death
(Fig. 3f, right panel). Although neither 4 mM nor 10 mM-
lidocaine induced caspase 3/7 activation was not statistically
significant, 250 μM Trolox suppressed 4 mM-lidocaine in-
duced the caspase activation. Likewise, flow cytometry ana-
lyses demonstrated the NAC treatment suppressed the
effects of 4 mM and 10 mM lidocaine on cell death (Fig. 3e
and Additional file 1: Figure S1F–S1H) and mitochondrial
voltage (Additional file 2: Figure S2E–S2G). LDH release by
10 mM lidocaine was not suppressed by NAC or Trolox
treatment (Additional file 3: Figure S3E).
Effects of an endogenous antioxidant on lidocaine-
induced cell death
Next, we chose to examine the effects of TRX, an en-
dogenous redox active protein, on lidocaine-induced cell
death. First, however, we evaluated the effects of GGA,
which is known to be an inducer of TRX [21, 22], on
SH-SY5Y cells. Consistent with the results obtained
using ROS scavengers, pre-treatment of SH-SY5Y cells
with 5 μM and 10 μM GGA for 2 h resulted in reduced
4 mM lidocaine-induced cell death and caspase-3/7 acti-
vation (Fig. 4a–c). 10 μM GGA suppressed ROS gener-
ation elicited by 4 mM lidocaine (Additional file 3:
Figure S3F). Even 10 μM GGA did not inhibit cell death
or LDH release induced by 10 mM lidocaine (Fig. 4b
and Additional file 3: Figure S3E). Surprisingly, however,
treatment with 10 μg/ml rhTRX failed to suppress
lidocaine-induced caspase-3/7 activation (Fig. 4d–f ).
Effects of synthetic antioxidants on mepivacaine and
bupivacaine-induced cell death
Lastly, we examined the in vitro effects of other local an-
esthetics on SH-SY5Y cells. Similar to those treated with
4 mM lidocaine, cells treated with 1 mM mepivacaine or
1 mM bupivacaine exhibited significantly reduced cell via-
bility and increased caspase-3/7 activation (Fig. 5a and b),
and these effects were blocked by treatment with 10 mM
NAC or 10 μM GGA (Fig. 5a and b). These findings indi-
cate that the anesthetic-mediated increases in cell death
observed in this study are not exclusive to lidocaine.
Discussion
In this study, we demonstrated that the local anesthetic
lidocaine suppresses the mitochondrial ETC in neuronal
SH-SY5Y cells in a dose- and time-dependent manner,
thereby attenuating mitochondrial membrane potential,
inducing ROS production, and activating caspase-9- and
caspase-3/7-mediated apoptosis and necrosis. Moreover,
we observed similar effects in cells treated with mepiva-
caine and bupivacaine. Intriguingly treatment with the an-
tioxidants NAC and Trolox successfully suppressed these
effects by scavenging the ROS derived from mitochondria.
Lidocaine induces two types of cell death
Multiple studies have reported that clinically relevant
concentrations (500 μM to 24 mM) of local anesthetics
such as lidocaine are capable of inducing cell death in
cells of neuronal origin as well as in established cell lines
derived from cancerous tissues [23, 24]. Consistent with
these findings, we demonstrated that 1 mM–10 mM
lidocaine was sufficient to promote cell death in neur-
onal SH-SY5Y cells and HeLa cervical carcinoma cells
(Figs. 1, 2, and Additional file 1: Figure S1).
Lidocaine induces apoptosis and necrosis in a dose-
dependent manner
There are at least two modes of cell death: apoptosis and
necrosis [25]. Apoptosis is a strictly regulated (pro-
grammed) process involving the activation of specific
cysteine proteases that is responsible for the ordered re-
moval of superfluous, aged, or damaged cells. Notably,
while this process plays critical roles in both health and
disease, necrosis is solely the outcome of severe and
acute injury. Apoptosis involves the regulated activity of
catabolic enzymes (proteases and nucleases) within a
near-to-intact plasma membrane, and is commonly ac-
companied by characteristic changes in nuclear morph-
ology and chromatin biochemistry.
In this study, lidocaine treatment promoted caspase-3/
7 and caspase-9 activation, as well as PARP cleavage, in
SH-SY5Y cells (Fig. 1c and d). As such, these data indi-
cate that lidocaine induces cell death via an authentic
apoptosis pathway. Meanwhile, flow cytometry analyses
demonstrated that treatment of cells with greater than
4 mM lidocaine especially 10 mM lidocaine also resulted
in increased numbers of PI- and annexin V-positive cells
(Additional file 1: Figure S1). These data strongly suggest
that lidocaine elicits both types of cell death in a dose-
dependent manner in vitro. Intriguingly, however, the ob-
served increase in caspase 3/7 but not in cell death with
LDH release, was significantly suppressed by treatment
with NAC, Trolox and GGA. The evidence suggests that
the antioxidants preferentially inhibit apoptosis rather
than necrosis.




Fig. 4 Effects of an endogenous antioxidant on lidocaine-induced cell death. a–c SH-SY5Y cells were exposed to the indicated concentrations of
lidocaine (0, 4, or 10 mM) for 24 h in the presence or absence of pretreatment with 5 or 10 μM teprenone (geranylgeranylacetone, GGA) for 24 h.
a Cell viability and b caspase-3/7 activity were evaluated by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] and Apo-ONE™ Homogeneous Caspase-3/7 Assay analysis, respectively (n = 3 for each). c Graphic depiction of the levels of cell death
among treated and untreated cell populations, as evaluated by flow cytometry (n = 4). The ratio with PI or annexin V positive cells were indicated
as dead cells. d–f SH-SY5Y cells were exposed to the indicated concentrations of lidocaine (0, 1, 4, or 10 mM) for 24 h in the presence or absence
of pretreatment with 10 μM recombinant human thioredoxin (rhTRX) for 2 h. Graphic depictions of (d) cell viability (n = 3), (e) caspase-3/7 activity
(n = 3), and (f) cell death (n = 4), as determined by MTS, Apo-ONE™ Homogeneous Caspase-3/7, and flow cytometry analysis, respectively. All data
were expressed as means ± standard deviations (SD). Differences between results were evaluated by two-way analysis of variance (ANOVA) followed
by Dunnett’s test for multiple comparisons in each group. *p < 0.05 compared with the control cell population at time 0 h (no treatment). #p < 0.05
compared with the control treatment population in the same group
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Functional mitochondria are necessary for lidocaine-
induced apoptosis but not for necrosis
Local anesthetics have been found to inhibit mitochon-
drial ETC at several points along the respiratory chain,
and to inhibit F1-ATPase activity and adenine-nucleotide
transport [26]. In this study, we also demonstrated the
lidocaine inhibited oxygen consumption by mitochondria
(Fig. 2c). Moreover, using ρ0 cells lacking mitochondrial
DNA, we showed that functional mitochondria are re-
quired for lidocaine-induced cell death following caspase
activation but not for lidocaine-induced necrosis with
LDH release (Fig. 2b and e). These data strongly suggests
that mitochondria comprise a critical target for lidocaine-
induced cell death, particularly for apoptosis.
It was previously reported that dysfunction of the
mitochondrial ETC due to mutations in OXPHOS sub-
units or treatment with chemical inhibitors is generally
associated with increased production of mitochondrial
ROS, including superoxide anions, hydroxyl radicals,
and hydrogen peroxide [27]. Specifically, inhibitor stud-
ies using isolated mitochondria demonstrated that com-
plexes I and III of the ETC can act as relevant sources of
mitochondrial ROS [27]. Consistent with these findings,
HEK293 cells treated with rotenone and antimycin A for
inhibition of complexes I and III, respectively, exhibited
increased ROS production and induction of oxidative
stress [28]. Meanwhile, ROS production was not ob-
served in ρ0 cells in this study (data not shown).
ROS derived from mitochondria promote lidocaine-
induced apoptosis
Another intriguing finding presented in this report was
that both lidocaine-induced apoptosis and necrosis were
ROS-dependent. The results presented in Fig. 3a clearly
demonstrate that lidocaine treatment induced ROS gener-
ation. And while the precise origin of these ROS remains
unclear, our findings strongly suggest that mitochondria
play a critical role in this process (Fig. 2b and c). As such,
these data imply that lidocaine-mediated cell death is
dependent on mitochondria. Consistent with this conclu-
sion, the mitochondrial DNA-deficient ρ0 cells were re-
sistant to lidocaine treatment (Fig. 3b). Moreover, our data
are consistent with a previous report demonstrating that
tetracaine-induced apoptosis in rat cortical astrocytes is
associated with increased ROS production [4].
Effect of antioxidants on lidocaine-induced cell apoptosis
Oxidative stress in response to various external stimuli
has been implicated in the induction of apoptosis. Spe-
cifically, oxygen free radicals induce DNA sequence
changes and rearrangements that may trigger apoptotic
cell death of neuronal cells. In this study, we provided
the first evidence that ROS scavengers such as NAC and
Trolox can significantly suppress lidocaine-induced cell
death in vitro. Conversely, while treatment with rhTRX
had no affect on apoptosis or necrosis, GGA, which is
known to induce TRX expression and is itself an antioxi-
dant, exerted a protective effect against lidocaine-induced
cell death. Although the molecular mechanisms underlying
these discrepancies are unclear, it is possible that extracel-
lular administration of rhTRX is an ineffective method for
modulating intracellular redox status [22, 29, 30]. Also,
GGA has been shown to promote the expression of heat
shock protein 70, which was reported to alleviate cellular
stress and exert cytoprotective effects [31, 32]. As such, the
observed beneficial effects of GGA on cell survival may be
a
b
Fig. 5 SH-SY5Y cells were exposed to the indicated concentrations of
local anesthetics in the presence or absence of the indicated
concentrations of 10 mMN-acetyl cysteine (NAC) and 10 μM
geranylgeranylacetone (GGA) for 24 h. a Levels of cell viability and (b)
caspase-3/7 activity were evaluated by MTS [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and
Apo-ONE™ Homogeneous Caspase-3/7 Assay analyses (n = 3 for each).
Data were expressed as means ± standard deviations (SD). Differences
between results were evaluated by two-way analysis of variance
(ANOVA) followed by Dunnett’s test for multiple comparisons.
*p < 0.05 compared with the control cell population at time 0 h
(no treatment). #p < 0.05 compared with the control treatment
population in the same group
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dependent on induction of HSP70 and not TRX. In any
case, future studies using cells that overexpress TRX may
better elucidate whether this protein can inhibit anesthetic-
induced cell death.
Limitations
There are several limitations to the present study. First,
the established SH-SY5Y and HeLa cell lines were used
exclusively for all experiments. Although SH-SY5Y cells
are derived from neuronal tissue and exhibit several
characteristics similar to neurons, our experimental re-
sults and conclusions cannot necessarily by extrapolated
to neuronal injuries induced by local anesthetics in an in
vivo setting. Furthermore, although we evaluated the ef-
fects of lidocaine on ρ0 cells, which lack mitochondrial
DNA, the majority of the data were obtained using HeLa
cells, primarily due to technical issues. Lastly, the results
presented in this study demonstrate that local anesthetics
negatively affect mitochondrial activity, thereby inducing
apoptosis; however, the specific molecular targets have yet
to be identified. As such, the identification of such targets
comprises a critical goal for future studies.
Conclusions
In this study, we demonstrated that the local anesthetics
lidocaine, mepivacaine, and bupivacaine induce two types
of cell death in neuronal cells in vitro. In particular, treat-
ment with 1–4 mM lidocaine promoted apoptosis, while
treatment with 10 mM lidocaine induced cell death with
LDH release. Moreover, our data demonstrate that these
compounds specifically target mitochondria, and that the
ROS produced by mitochondria play an integral role in the
observed induction of apoptosis. Lastly, we demonstrated
that scavenging of ROS with antioxidants such as NAC,
Trolox, and GGA preserved mitochondrial voltage and
prevented apoptosis by suppressing caspase activation.
Additional files
Additional file 1: Figure S1. Analysis of cell apoptosis by FACS. Levels
of cell apoptosis were measured using an Annexin V-FITC Apoptosis
Detection Kit (BioVision, Milpitas, CA, USA), according to the manufacturer’s
instructions. For these analyses, SH-SY5Y cells were seeded into 6-well plates
(3 × 105 cells/well) and incubated overnight. The following day, cells were
treated with the indicated concentrations of the appropriate drug(s) for
varying lengths of time and harvested by centrifugation at 1200 rpm for
3 min. The culture supernatants were discharged, and the resulting pellets
were resuspended in a mixture comprised of 500 μl binding buffer, 5 μl
Annexing V-FITC, and 5 μl propidium iodide (PI; 50 μg/ml) for 5 min at room
temperature in the dark and analyzed using a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA, USA). (PDF 2009 kb)
Additional file 2: Figure S2. Mitochondrial membrane potential (ΔΨm).
Mitochondrial membrane potential was determined by flow cytometry using
a MitoPT™ JC-1 Assay Kit (ImmunoChemistry Technologies, Bloomington,
MN, USA), according to the manufacturer’s instructions. For these analyses,
SH-SY5Y cells were seeded into 6-well plates (3 × 105 cells/well) and
cultivated overnight. The following day, cells were treated with the
indicated concentrations of the appropriate drug(s) for varying lengths
of time and then pelleted by centrifugation at 1200 rpm for 3 min.
Supernatants were discharged, and cells were resuspended in JC-1,
incubated at 37 °C for 15 min in the dark, and collected by centrifugation
at 1200 rpm for 3 min. Supernatants were again discharged and the
remaining cell residues were suspended in 500 μl assay buffer. Samples
were subsequently analyzed using a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA) equipped with CellQuest Pro™ software for
the detection of red JC-1 aggregates (590 nm emission) or green JC-1
monomers (527 nm emission). (PDF 2041 kb)
Additional file 3: Figure S3. Results of HeLa cell-derivatives EB8 and
HeEB1. (A) Oxygen consumption rate of HeLa cells, EB8 and HeEB1cells
were demonstrated. (B) Graphic depiction of reactive oxygen species
(ROS) production in HeLa cells and EB8 cells exposed to the indicated
concentrations of lidocaine (0, 4, or 10 mM) for 6 h (n = 3). Data depict
the ratio of ROS production in treated cells compared to that in the
untreated control group (HeLa cells). (C) Activities of Caspase3/7 of HeLa
cells and HeEB1 cells were demonstrated. (D) Levels of cell death were
measured using an Annexin V-FITC Apoptosis Detection Kit evaluated by
FACS were demonstrated. (E) Graphic depiction of the levels of cell death
among treated and untreated cell populations. Cell death was evaluated
by measuring the levels of lactate dehydrogenase (LDH) within culture
supernatants (n = 3) in the presence or absence of 10 mM N-acetyl
cysteine (NAC), 250 μM Trolox and 10 μM GGA. Control is LDH activity
treated by lysis buffer. (F) Graphic depiction of reactive oxygen species
(ROS) production in SH-SY5Y cells exposed to 4 mM) for 6 h (n = 3) in the
presence or absence of 10 mM N-acetyl cysteine (NAC), 250 μM Trolox
and 10 μM GGA. Data depict the ratio of ROS production in treated cells
compared to that in the untreated control group. Data presented in A–E
expressed as means ± standard deviations (SD). #p < 0.05 compared with
the control cell population at the same time period. (PDF 587 kb)
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